Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.32−0.09 (-2.64%)
Close on Nov 17, 2026Market cap $264.95MP/E –Yield –
Prelude Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Prelude Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$33.26M. For fiscal 2025 it was -$56.30M. The highest annual figure on record is -$25.67M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$56.30M | – |
| FY2024 | Dec 31, 2024 | -$102.89M | – |
| FY2023 | Dec 31, 2023 | -$107.06M | – |
| FY2022 | Dec 31, 2022 | -$83.73M | – |
| FY2021 | Dec 31, 2021 | -$83.53M | – |
| FY2020 | Dec 31, 2020 | -$46.18M | – |
| FY2019 | Dec 31, 2019 | -$25.67M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.57M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.69M | – |
| Q4 FY2025 | Dec 31, 2025 | $23.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.08M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.23M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.74M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.30M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.06M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$25.68M | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.13M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.93M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.44M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.90M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.77M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.85M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.51M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.90M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.92M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.47M | – |
See a number that looks wrong?